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with a risk factor, (heart and respiratory failure) the res-
piratory infection probability is 4.3%, inducing hospital-
izations in 37% of cases. RESULTS: Direct costs were
calculated as the sum of costs due to medication, consul-
tations, hospitalization and respiratory physiotherapy.
The impact of indirect cost should also be taken into con-
sideration. Our estimation evaluated them four times in-
ferior to those due to influenza. With regards to the risk
of hospitalization (1%–3% or 5%), the average cost of
RSV infection varies, according to a societal perspective,
from 750 to 1103 Euros. CONCLUSION: The annual fi-
nancial burden of RSV disease from the payer perspective
would be between 306 to 612 millions Euros. This an-
nual figure represents a third of the cost allocated to in-
fluenza, which justifies the efforts of research in view of
making emerge a vaccine against the RSV.
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OBJECTIVES: Asthma bronchiale (AB) and chronic bron-
chitis (CB) are common chronic disorders with high rates
of prevalence. We performed a cost of illness study that
aimed to assess the economic burden of these disorders in
Germany. To the best of our knowledge, we used the first
time data for entire Germany, in contrast with the few
previous studies. METHODS: We obtained in a retro-
spective analysis secondary data from governmental insti-
tutions as well as from pharmaceutical industry. Re-
source use was based on 1996 schedules and costs were
estimated in 1996 DM. We chose the cost perspective of
sickness funds to estimate direct costs. The human capital
approach was applied for the calculation of indirect
costs. RESULTS: Total estimated costs were DM 5.81
billion related to AB, and DM 20.17 billion related to
CB. We did not include outpatient physician services in
the calculation of direct costs in lack of adequate data.
Therefore, direct costs represented only 33% and 22% of
total estimated costs, respectively. The most important
cost driver of direct costs was outpatient prescribed med-
icines, followed by hospitalization. Outpatient prescribed
medicines accounted for 55% and 63% of the direct
costs, respectively. Of the indirect costs of AB 43% were
associated with early retirement. Loss of work was with
75% by far the largest single cost driver of indirect costs
due to CB. CONCLUSIONS: Findings from this study
for Germany show the evident importance of outpatient
prescribed medicines as cost driver of direct costs of AB
as well as of CB. Furthermore, this study underlines the
major role of loss of work concerning indirect costs of
CB. The data suggest that therapeutic progress and cessa-
tion of smoking can provide distinctive savings of direct
costs and even more of indirect costs of AB and CB.
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OBJECTIVE: To determine the appropriateness of using
prescription treatment to measure asthma severity in a
retrospective claims database. METHODS: All patients
within PharMetric’s Integrated Outcomes Database pos-
sessing a diagnosis of asthma (ICD-9-CM  493) and a
prescription claim for an asthma medication during 1997–
1998, were eligible for study inclusion. Patients with less
than 12 months of enrollment following the initial asthma
diagnosis, or a diagnosis of chronic obstructive pulmo-
nary disease (COPD) or cystic fibrosis (CF) were ex-
cluded from the analysis. Patients were assigned into se-
verity levels based on the combination of asthmatic
regimens received during the study period: Level 1 
Short Acting Beta Agonist (SABA) Only; Level 2  one
controller medication (Mast Cell Stabilizer, Inhaled Corti-
costeroid, or Leukotriene Modifying Agent); Level 3  2
Controllers (above list  Long Acting Beta Agonis); Level
4  3 or more controllers (above list  Long Acting Beta
Agonist). Patient demographics, asthma-specific charges,
and comorbid conditions were captured for each patient
during the study period. RESULTS: 124,076 patients met
the inclusion criteria. The mean age was 23.6 years (SD 
19.6), and 53.0% were female. Over half (50.5%) of pa-
tients were in Level 1, while only 0.9% were in Level 4.
Mean age and percentage of females increased with in-
creasing severity. The mean annual asthma-specific charge
per patient was $675.73 (SD  $1992.10), and ranged
from $379 for Level 1 patients to $1,414 for Level 4 pa-
tients. Prevalence of diabetes, hypertension, and depres-
sion increased with increasing severity, while upper-
respiratory and lower-respiratory infections decreased.
CONCLUSION: The use of treatment regimen appears
to be a viable alternative for measuring severity of asthma
in retrospective analyses, however further research is needed.
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BACKGROUNDS: Nonsteroidal anti-inflammatory drugs
(NSAIDs) are used in nearly every patient with rheuma-
toid arthritis (RA) but their use can be associated with
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side effects, which may be prevented with prophylactic
prescription of misoprostol, omeprazole, or famotidine.
Recently marketed COX-2 specific inhibitor (COX-2) af-
fords protection against gastropathy. OBJECTIVE: To
assess cost-effectiveness of NSAIDs vs COX-2 and NSAIDs
with co-treatments to prevent GI toxicity in the treatment
of RA. METHODS: Markov models were used to simu-
late a cohort of RA patients with approximately 2.5:1 fe-
male to male ratio and 50 years, taking disease modifying
antirheumatic drugs and one of following strategies:
NSAIDs without prophylaxis, COX-2, NSAIDs with mis-
oprostol, omeprazole, or famotidine. Data on incidence,
costs and consequences of adverse events from treat-
ments were taken from the literature. Costs were mea-
sured in 1999 US dollars and health effects expressed as
quality-adjusted life years (QALYs). Sensitivity analyses
were performed. Costs and health outcomes were dis-
counted at a rate of 3% per year. RESULTS: Among the
strategies to prevent GI toxicity, COX-2 was the most
cost-effective strategy and famotidine was the least cost-
effective strategy. The incremental C/E (cost/effective-
ness) ratio between no prophylaxis and COX-2 is 62,278
($/QALY). Sensitivity analyses using incidence rates were
robust. CONCLUSIONS: COX-2 is the best option
among the strategies to prevent GI toxicity. However, the
incremental C/E between no prophylaxis and COX-2
strategies is over 60,000 ($/QALY).
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OBJECTIVE: To compare the total costs associated with
two different anti-TNF agents used in the treatment of
moderate to severe rheumatoid arthritis: etanercept, which
can be administered at home by a subcutaneous injection,
versus infliximab, which requires an intravenous infusion in
day-care. METHODS: An economic model was con-
structed to determine the costs of both treatments. The cost
Strategy QALY Costs ($)
C/E
($/QALY)
No prophylaxis 11.45 43,474 —
Misoprostol 11.53 52,817 Extended Dominated
COX-2 11.68 57,798 62,278
Famotidine 11.69 87,606 Dominated
Omeprazole 11.71 63,911 203,766
evaluation included direct medical, direct non-medical and
indirect costs. The perspective was that of the Dutch soci-
ety. The analysis was performed for the adult RA popula-
tion eligible for treatment with both agents. The base case
analysis compared a monotherapy with etanercept versus a
combination therapy with infliximab-MTX. Data for the
economic model came from published literature, expert
opinion and official price and tariff lists. RESULTS: The
analysis from the society perspective showed that the total
annual drug costs per patient do not differ substantially be-
tween infliximab and etanercept, with costs of NLG 31,526
(EURO 14,306) and NLG 31,334 (EURO 14,219) respec-
tively. However the other medical costs are substantially
higher for infliximab, which is due to the additional costs
associated with day-care and use of MTX (NLG 12,621;
EURO 5,727). Overall treatment with infliximab is more
expensive than treatment with etanercept with total costs of
NLG 45,115 (EURO 20,472) and NLG 31,621 (EURO
14,349), respectively (43.7% increase). The sensitivity anal-
ysis showed that the results vary with dosing and dosing in-
terval for infliximab. CONCLUSION: Based on the as-
sumptions used in the model, we may conclude that the use
of etanercept compares favourable with infliximab: the to-
tal costs are substantially lower, while the clinical outcomes
of etanercept are at least equivalent to those of infliximab.
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OBJECTIVE: To evaluate the total resource consump-
tion and the costs for diagnostics and treatments per pa-
tient with severe chronic polyarthritis (cp) from the third
party payers’ (TPP) perspective in Germany. METH-
ODS: A retrospective cross-sectional cost of illness-study
was performed. Patients (18 to 75 years) with acute dis-
ease activity of cp with a history of therapy failure with
MTX over a minimum of 4 months or failure of more
than one basic treatment were included. Hospital and
practice data was abstracted from patient’s records. Sta-
tistical analysis and cost evaluation were performed by
using the SAS package. Cost data was taken from pub-
lished German tariff and price lists. RESULTS: The mean
age of the patients was 56 years, 71.2% were females.
The mean onset of the disease was 11.2 years ago. The
total average costs of outpatient care (n  191 patients)
were approximately 3,445 DM (95% CI: 2,981-3,907
DM) and for inpatient care (n  76 patients) 10,433 DM
(95% CI: 8,800–12,067 DM) per year. Concerning out-
patient care drug therapy could be identified as the most
